Anti-vaccination rhetoric from Washington has cascading effect for vaccine makers: BMO's Seigerman

Key Concepts:

• Anti-vaccine rhetoric and its impact on public health
• COVID-19 vaccine market dynamics (Pfizer, BioNTech, Moderna)
• Insurance coverage and accessibility of vaccines
• Political influence on vaccine perception
• Pfizer's diversification into oncology
• Diabetes drug market and key data readouts (specifically, the data)
• Efficacy and side effect profiles of diabetes drugs (nausea, vomiting)
• Food effect on oral semaglutide

1. Impact of Anti-Vaccine Rhetoric:

• The general anti-vaccine sentiment is detrimental to public health.
• While the COVID-19 vaccine for children represents a small portion of Pfizer and BioNTech's sales, the rhetoric affects other crucial vaccines like HPV and MMR.
• The analyst mentions rhetoric coming out of Florida as a negative influence.

2. COVID-19 Vaccine Market and Key Players:

• Pfizer & BioNTech: COVID-19 vaccine sales are primarily contracted outside the United States, focusing on older, at-risk populations.
• Moderna: Their entire business is heavily reliant on COVID-19 vaccines.
• Pfizer: More diversified; COVID-19 vaccine is a shrinking part of their business. They are focusing on oncology.

3. Insurance Coverage and Vaccine Accessibility:

• Insurance coverage and pharmacist availability (vaccines without prescription) are crucial for vaccine uptake.
• The analyst believes that removing insurance coverage for common vaccines like MMR and HPV would likely cause backlash.
• The COVID-19 vaccine is a "flashpoint" due to political pushback and debates over data sufficiency.

4. Pfizer's Diversification into Oncology:

• Pfizer is shifting its focus to oncology, which is a key area for investors.
• They have a significant partnership with Bristol-Myers Squibb for a Pd-l1, VEGF bispecific in lung cancer.
• Despite the shift, vaccine-related news can still cause market jitters among general investors.

5. Diabetes Drug Market and Key Data Readouts:

• The analyst is looking forward to the diabetes meeting in Europe.
• The primary focus is on the data, specifically understanding why it underperformed.
• Key questions include:
  • Is a 11-12% efficacy good enough?
  • Is a 16% efficacy needed?
  • What is an acceptable rate of nausea and vomiting?
  • What is the impact of food on high-dose oral semaglutide?

6. Food Effect on Oral Semaglutide:

• The "food effect" on high-dose oral semaglutide is considered a potential headwind for Novo Nordisk.

Synthesis/Conclusion:

The discussion highlights the complex interplay of public health, politics, and market dynamics in the pharmaceutical industry. Anti-vaccine sentiment poses a broad threat beyond COVID-19, while insurance coverage and accessibility are critical for vaccine adoption. For pharmaceutical companies like Pfizer, diversification into areas like oncology is crucial for long-term growth, even as vaccine-related news continues to influence market perception. In the diabetes drug market, upcoming data readouts will be pivotal in determining the clinical and commercial viability of new treatments, with factors like efficacy, side effects, and food interactions playing key roles.